-
USP7–PKM2 Control in Severe Acute Pancreatitis
2026-09-11
A 2025 study links USP7 deubiquitination of PKM2 to glycolytic metabolic reprogramming and pro-inflammatory macrophage polarization in severe acute pancreatitis. Its combination of genetic perturbation, metabolic flux analysis, protein-interaction assays, and pharmacological rescue positions PKM2 as a mechanistic—not merely correlative—node in pancreatic inflammation.
-
MLKL Polymerization, LMP, and Necroptosis
2026-09-11
The reference study identifies lysosomal membrane permeabilization as a mechanistic step linking MLKL polymerization to necroptotic cell death. Using live-cell imaging, lysosomal tracking, and cathepsin B perturbation, it shows that MLKL-driven lysosomal damage releases cathepsin B before plasma membrane rupture and that reducing cathepsin B activity protects cells.
-
PKM2 Inhibitor 3k: From Glycolysis to Translation
2026-09-10
PKM2 inhibitor (compound 3k) offers a translational bridge between tumor metabolism and immunometabolic research. This article examines its mechanism, preclinical evidence, workflow design, competitive positioning, and the strategic questions required to advance pyruvate kinase M2 inhibition beyond a conventional product-page narrative.
-
CFDA-SE for Proliferation and Migration Tracking
2026-09-10
CFDA-SE converts intracellular esterase activity into a division-sensitive fluorescence record for viable cells, enabling quantitative proliferation and migration studies. Used alongside surface-proteome methods such as nanobody-TurboID, it separates cell behavior from the molecular neighborhoods that may regulate it.
-
NVP-BGJ398 phosphate: FGFR Research Workflow
2026-09-09
NVP-BGJ398 phosphate connects potent FGFR1–3 pathway inhibition with practical oncology, chondrocyte, and skeletal-disease workflows. This guide translates biochemical potency into stepwise assays, genotype-aware controls, and troubleshooting strategies for more reproducible translational research.
-
Lidocaine With Epinephrine Shortage: Evidence and Solutions
2026-09-09
Bodie, Brodell, and Helms analyze the persistent U.S. shortage of lidocaine with epinephrine and identify both manufacturer-level and supply-chain causes. Their practical contribution is a stewardship framework that combines lower-volume injections, reduction of avoidable vial waste, concentration adjustment, and cautious management of prepared syringes while preserving procedural quality and safety.
-
PKM2 Inhibitor (Compound 3k): Assay Logic
2026-09-08
PKM2 inhibitor (compound 3k) offers a selective way to interrogate pyruvate kinase M2, cancer metabolism, and immunometabolic signaling. This article explains how to interpret its biochemical, cellular, xenograft, and macrophage data without conflating metabolic inhibition with pathway-specific proof.
-
PKM2 inhibitor (compound 3k) Workflow Guide
2026-09-07
Build a PKM2-centered workflow that connects glycolytic flux, cancer-cell proliferation, and macrophage polarization. This guide separates product-backed benchmarks from practical starting conditions for oncology, ovarian cancer therapy, and immunometabolism experiments.
-
Ivacaftor During Prolonged Tezacaftor/Elexacaftor
2026-09-07
This in vitro study clarifies why ivacaftor can provide a net functional benefit during prolonged tezacaftor/elexacaftor exposure, despite earlier reports of reduced F508del-CFTR correction after chronic potentiator treatment. Using differentiated human nasal epithelia and Ussing chamber electrophysiology, the authors show that ivacaftor increases constitutive CFTR activity specifically in the triple-modulator context.
-
SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors
2026-09-05
The 2024 reference study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition and sustains cancer stem cell-like properties in thymic epithelial tumors. Integrated genomic, functional, single-cell, chromatin, interaction, and phosphoproteomic analyses connect SNAI1 to PIK3R2, phosphorylated EphA2, and downstream GSK3β/β-catenin signaling, providing a mechanistic framework for future target validation.
-
Acetoacetic Acid Sodium Salt: Metabolic Research Guide
2026-09-04
Acetoacetic acid sodium salt, also called sodium 3-oxobutanoate, is a water-compatible source of the ketone body acetoacetate. Its defined identity, reported solubility, and 98% purity support controlled energy metabolism research, but the compound does not by itself reproduce diabetic ketoacidosis or the endocrine conditions that cause it.
-
Müller-Cell PEDF Links Angiopoietins to Neuron Survival
2026-09-04
Younis and colleagues show that angiopoietin-1 and angiopoietin-2 regulate retinal neuronal survival indirectly through Müller-cell Tie-2/PI3K/Akt signaling and pigment epithelium-derived factor. The co-culture, knockdown, hypoxia, and rescue experiments provide a mechanistic framework for studying retinal neurovascular interactions and evaluating pathway-directed interventions.
-
Cy5-UTP (Cyanine 5-UTP): Lab Q&A
2026-09-04
This scenario-based guide explains how Cy5-UTP (Cyanine 5-UTP), SKU B8333, can add a far-red RNA readout to viability, proliferation, cytotoxicity, FISH, and neuronal granule workflows. It separates documented product specifications from practical recommendations so researchers can improve assay interpretation without overstating what fluorescent RNA labeling can measure.
-
Cyclo (-RGDfC) for Reliable Integrin Assays
2026-09-03
Cyclo (-RGDfC) (SKU A8790) offers a structured c(RGDfC) ligand for investigating αvβ3 integrin-dependent adhesion, proliferation, viability, and cytotoxicity phenotypes. This scenario-based guide connects product handling, assay controls, data interpretation, and 96-well workflow considerations to improve experimental consistency without overstating product-specific biological validation.
-
LINC01977 Super-Enhancer Hijacking in LUAD
2026-09-02
Zhang et al. identify LINC01977 as a super-enhancer-hijacked long noncoding RNA that promotes early-stage lung adenocarcinoma through a feed-forward TGF-β/SMAD3 circuit. The study connects tumor-associated macrophage signaling, enhancer reprogramming, CREBBP/EP300 coactivator recruitment, and ZEB1 regulation, providing a mechanistic framework for lung adenocarcinoma research and epigenetics research.